These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29317292)

  • 21. Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis.
    Tsuchiya K; Ishikawa K; Tani S; Oshita Y; Kuroda T; Yamamura R; Emori H; Maruyama H; Matsuoka A; Kudo Y; Shirahata T; Toyone T; Nagai T; Inagaki K
    Clin Interv Aging; 2019; 14():1445-1450. PubMed ID: 31496671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical femoral fractures bilaterally in a patient receiving denosumab.
    Drampalos E; Skarpas G; Barbounakis N; Michos I
    Acta Orthop; 2014 Feb; 85(1):3-5. PubMed ID: 24171686
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug holidays in women treated for postmenopausal osteoporosis.
    McClung MR
    Menopause; 2018 Oct; 25(10):1152-1154. PubMed ID: 30044265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.
    Betella N; Biamonte E; Matarazzo C; Piccini S; Olivetti R; Cellini M; Lania AG; Mazziotti G
    Minerva Endocrinol; 2020 Sep; 45(3):165-171. PubMed ID: 32186164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
    Kendler DL; Chines A; Brandi ML; Papapoulos S; Lewiecki EM; Reginster JY; Muñoz Torres M; Wang A; Bone HG
    Osteoporos Int; 2019 Jan; 30(1):71-78. PubMed ID: 30244369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical vertebral fractures following denosumab discontinuation.
    Polyzos SA; Terpos E
    Endocrine; 2016 Oct; 54(1):271-272. PubMed ID: 27393301
    [No Abstract]   [Full Text] [Related]  

  • 28. Dilemma of denosumab therapy: rebound fractures with denosumab cessation or dose delay.
    Herath M; Wong P; Milat F
    Intern Med J; 2021 Feb; 51(2):297-298. PubMed ID: 33631850
    [No Abstract]   [Full Text] [Related]  

  • 29. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
    Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
    Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Boonen A; Dirksen CD; Ben Sedrine W; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):19-28. PubMed ID: 23402442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison table: some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2020 Jul; 62(1546):e112-e114. PubMed ID: 32728010
    [No Abstract]   [Full Text] [Related]  

  • 33. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remarkable loss of bone mineral density in 6 months after denosumab discontinuation: a case report.
    Maezumi Y; Kamimura M; Nakamura Y; Takahashi J
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):218-221. PubMed ID: 33087002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab after 8 years.
    Reid IR
    Osteoporos Int; 2015 Dec; 26(12):2759-61. PubMed ID: 26475285
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
    Diédhiou D; Cuny T; Sarr A; Norou Diop S; Klein M; Weryha G
    Ann Endocrinol (Paris); 2015 Dec; 76(6):650-7. PubMed ID: 26639186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab (prolia) for treatment of postmenopausal osteoporosis.
    Johnson GL
    Am Fam Physician; 2012 Feb; 85(4):334-6. PubMed ID: 22335312
    [No Abstract]   [Full Text] [Related]  

  • 39. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P
    Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
    Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
    Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.